Theravance Uses Organ-Selective R&D To Advance GI, Pulmonary Candidates
Executive Summary
Company develops selective JAK inhibitors for IBD and pulmonary disease that are intended to clear the body before systemic side effects can occur. It also has a drug candidate for NOH that analysts think is underappreciated.
You may also be interested in...
Deal Watch: Pfizer Licenses Skin-Targeted JAK Inhibitor Portfolio From Theravance
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.
Theravance Banks $100m As J&J Bets Big On IBD Drug
If the JAK inhibitor codenamed TD-1473 proves effective in Crohn’s disease and ulcerative colitis, the clinical, regulatory and commercial know-how in IBD from partner Janssen could help Theravance pocket $1bn.
Theravance Pushes On With Gastroparesis Candidate Amid Mixed Data
Theravance is working out what to do next with its investigational drug for gastroparesis after it produced mixed data in a Phase IIb trial in this underserved indication.